A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
무작위 임상시험
4/5 보강
TL;DR
Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated and the key secondary efficacy endpoint was proportion of patients achieving 30% improvement in SALT30.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
47 patients, respectively.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[LIMITATIONS] Only a single-dosage regimen of each study drug was included. [CONCLUSION] Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.
📑 코퍼스 인용 관계
· 인용됨 51
📑 인용한 논문 (6) ▾
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alo… Cureus · 2026
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study. American journal of clinical dermatology · 2026
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Al… Dermatology and therapy · 2026
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network… Frontiers in pharmacology · 2025
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A … Journal of clinical medicine · 2025
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for mod… Frontiers in medicine · 2025
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
경구 야누스 인산화효소 억제제(Janus kinase inhibitor, JAK 억제제)인 리트레시티닙(ritlecitinib)과 브레포시티닙(brepocitinib)이 두피 모발 50% 이상 소실을 동반한 원형 탈모증(alopecia areata) 환자에서 보이는 유효성과 안전성을 평가하고자 한 제2a상 임상시험이다.
【방법】
환자를 리트레시티닙(48명), 브레포시티닙(47명), 위약(47명)의 1일 1회 경구 투여군으로 무작위 배정하였다. 1차 평가변수는 24주째 탈모중증도평가도구(Severity of Alopecia Tool, SALT) 점수의 기저치 대비 변화량이었고, 주요 2차 평가변수는 SALT 점수 30% 이상 개선 달성 환자 비율이었다.
【주요 결과】
24주째 위약 대비 SALT 점수 개선 폭은 리트레시티닙 31.1점, 브레포시티닙 49.2점으로 두 약제 모두 위약보다 유의하게 우수하였다(P < .0001). SALT 30% 개선 달성률은 리트레시티닙 50%, 브레포시티닙 64%인 반면 위약은 2%에 그쳤으며, 중대한 이상반응(횡문근융해증, rhabdomyolysis)은 브레포시티닙군에서만 2명 발생하였다.
【임상적 시사점 (성형외과 의사 관점)】
모발이식이나 국소치료로 한계가 뚜렷했던 광범위 원형 탈모증 환자에게 경구 JAK 억제제가 의미 있는 모발 재성장 대안이 될 수 있어, 탈모 상담 시 약물치료 의뢰·병행 전략을 고려할 수 있다. 다만 브레포시티닙은 횡문근융해증 등 중대한 이상반응이 보고되어 환자 선별과 안전성 모니터링이 필요하며, 모발이식 시점 결정 전 약물치료로 활성 병변의 안정화 여부를 먼저 평가하는 것이 바람직하다.
[BACKGROUND] Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments.
[OBJECTIVE] To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair loss.
[METHODS] Patients were randomized to once-daily ritlecitinib, brepocitinib, or placebo. The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT).
[RESULTS] The ritlecitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. At week 24, least-squares mean difference from placebo in SALT score change from baseline was 31.1 (95% confidence interval [CI], 18.8-43.5) for ritlecitinib and 49.2 (95% CI, 36.6-61.7) for brepocitinib (P < .0001 for both comparisons with placebo). SALT was achieved by 50% (90% CI, 38%-62%) of patients receiving ritlecitinib, 64% (90% CI, 51%-75%) receiving brepocitinib, and 2% (90% CI, 0%-9%) receiving placebo. Two patients experienced a serious adverse event (rhabdomyolysis) in the brepocitinib group only.
[LIMITATIONS] Only a single-dosage regimen of each study drug was included.
[CONCLUSION] Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.
[OBJECTIVE] To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair loss.
[METHODS] Patients were randomized to once-daily ritlecitinib, brepocitinib, or placebo. The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT).
[RESULTS] The ritlecitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. At week 24, least-squares mean difference from placebo in SALT score change from baseline was 31.1 (95% confidence interval [CI], 18.8-43.5) for ritlecitinib and 49.2 (95% CI, 36.6-61.7) for brepocitinib (P < .0001 for both comparisons with placebo). SALT was achieved by 50% (90% CI, 38%-62%) of patients receiving ritlecitinib, 64% (90% CI, 51%-75%) receiving brepocitinib, and 2% (90% CI, 0%-9%) receiving placebo. Two patients experienced a serious adverse event (rhabdomyolysis) in the brepocitinib group only.
[LIMITATIONS] Only a single-dosage regimen of each study drug was included.
[CONCLUSION] Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.
- p-value P < .0001
- 95% CI 36.6-61.7
【연구 목적】 경구 야누스 인산화효소 억제제(Janus kinase inhibitor, JAK 억제제)인 리트레시티닙(ritlecitinib)과 브레포시티닙(brepocitinib)이 두피 모발 50% 이상 소실을 동반한 원형 탈모증(alopecia areata) 환자에서 보이는 유효성과 안전성을 평가하고자 한 제2a상 임상시험이다.
APA 7
King, B., Guttman-Yassky, E., Peeva, E., Banerjee, A., Sinclair, R., Pavel, A. B., Zhu, L., Cox, L. A., Craiglow, B., Chen, L., Banfield, C., Page, K., Zhang, W., & Vincent, M. S. (2021). A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.. Journal of the American Academy of Dermatology, 85(2), 379-387. https://doi.org/10.1016/j.jaad.2021.03.050
Vancouver
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Jour. Amer. Acad. Derm.. 2021;85(2):379-387. doi:10.1016/j.jaad.2021.03.050
AMA 11
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Jour. Amer. Acad. Derm.. 2021;85(2):379-387. doi:10.1016/j.jaad.2021.03.050
Chicago
King, B., Guttman-Yassky, E., Peeva, E., Banerjee, A., Sinclair, R., Pavel, A. B., Zhu, L., Cox, L. A., Craiglow, B., Chen, L., and .... 2021. "A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results." Journal of the American Academy of Dermatology 85 (2): 379-387. https://doi.org/10.1016/j.jaad.2021.03.050
MLA 9
King, B., et al. "A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results." Journal of the American Academy of Dermatology, vol. 85, no. 2, 2021, pp. 379-387. doi:10.1016/j.jaad.2021.03.050.
PMID
33757798 ↗
추출된 의학 개체 (NER)
해부
두피 scalp
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 해부 | scalp
|
두피 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
- Alopecia Areata: Current Treatments and New Directions.
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis…
- Alopecia Areata: An Updated Review for 2023.
- Baricitinib for the Treatment of Alopecia Areata.
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
- Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways.
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-…
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatm…
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- Ritlecitinib: First Approval.
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Rev…
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia ar…
- Characterizing the relationships between patient-reported outcomes and clinician assessments of alop…
- Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Ar…
- Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
- Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover …
같은 제1저자의 인용 많은 논문 (5)
- Two Phase 3 Trials of Baricitinib for Alopecia Areata.
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
- Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Alopecia areata: A multifactorial autoimmune condition.
TL;DRVarious genetic and environmental factors that cause autoimmunity are discussed and the immune mechanisms that lead to hair loss in alopecia areata patients are described.